China to Announce New National Drug Reimbursement List

According to sources, China is getting close to announcing a revised National Reimbursement Drug List (NRDL), the group of drugs covered by China's national insurance plan. There will be 300 additions, 130 of which will be chemical drugs. The rest will be traditional Chinese medicines. Last May, China negotiated steep price cuts on several breakthrough drugs, and these still-expensive treatments are expected to become part of the new list. These include Viread from GlaxoSmithKline; Iressa from AstraZeneca; and Icotinib from Zhejiang Beta Pharma. More details.... Stock Symbols: (NYSE: GSK) (NYSE: AZN ) Share this with colleagues: // //